Shows
The Fitness Pain Free ShowWhat Physical Therapists NEED to Know About MCL Injuries📌 FREE Guide - MCL Injury Evidence Based Exercise "Cheat Sheet" https://fitnesspainfree.com/programs/mcl-injury-cheat-sheet-lead-magnet/ Thanks for watching!👉 Check out the FPF Mini Course with "7 Reasons Why People Get Hurt in the Gym and What to do About It." https://fitnesspainfree.com/programs/fpf-certification-presale-page/ 👉 Rotator Cuff MASTER Course (Insiders) - https://fitnesspainfree.com/programs/fpf-insiders/ Show Notes:- https://fitnesspainfree.com/2025/03/what-physical-therapists-need-to-know-about-mcl-injuries/In today's episode we go over What Physical Therapists NEED to Know About MCL Injuries - FPF Show Episode 1640:00 Introduction1:32 How common are MCL injuries? (prevalence...2025-03-1557 min
The Shelbourne Knee Center PodcastPatients Place: MCL TearsWelcome to another engaging episode of Patient's Place, specifically designed to break down complex medical topics for patients and non-clinicians. This episode dives deep into the world of Medial Collateral Ligament (MCL) tears, focusing on common mechanisms, symptoms, and treatment options.
Join the discussion as we explore how MCL injuries are sustained, typically through sports-related incidents such as a hit to the knee. We discuss the importance of understanding the signs, including medial knee pain, and the diagnostic process that follows.
The episode also demystifies the examination procedures you might encounter if you suspect an...2025-01-0834 min
The Optimal Body368 | MCL Strain Around the Knee? What You Need To KnowIn this episode of the Optimal Body Podcast, hosts Doc Jen and Doctor Dom, both doctors of physical therapy, discuss MCL (medial collateral ligament) strains. They explain the anatomy and function of the MCL, common injury mechanisms, and the grading of MCL injuries. Emphasizing the importance of foot health and mobility for knee stability, they outline the rehabilitation process, highlighting the role of physical therapy in recovery. The episode underscores the significance of proper rehabilitation to regain strength and stability, offering valuable insights for women looking to understand and manage MCL injuries effectively.
FREE plan + a chance...2024-08-0524 min
ReachMD CMEChairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCLCME credits: 0.50
Valid until: 23-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment...2024-07-2300 min
Ortho Eval Pal: Optimizing Orthopedic Evaluations and Management SkillsEvaluating and Treating MCL Injuries | OEP340Send us a textToday, I talk about Evaluating and Treating MCL Injuries.I discuss...-Anatomy of the MCL-Evaluating the MCL and special tests-Surrounding structures that can be affected when the MCL is injured.-Treatment recommendations and so much more!!(Video) MCL Evaluation(Video) Positive Brush Test(Video) ACL EvaluationMeet our new sponsor: Tread Labs!!👉I've been...2024-05-2816 min
The New Grad Physio PodcastMCL Knee Acute Injury ManagementUnless you have seen loads of medial collateral ligament (MCL) injuries previously it is likely you might not know the best way to manage this type of injury...
Especially given the lack of teaching you were given around these types of problems at University!
So here is some help!
In this episode you will discover some of the key considerations around early MCL injury management including...
- Bracing protocols
- The best types of braces to use
- The clinical reasoning for bracing all grades of MCL...2024-05-0221 min
TALKS4LIFEJak SKUTECZNIE leczyć uszkodzenie więzadła pobocznego piszczelowego (MCL)?Uszkodzenie więzadła pobocznego piszczelowego to jedna z częstszych kontuzji, do których dochodzi u osób aktywnych fizycznie. Narty i sporty kontaktowe to typowe okoliczności dla tego urazu, ale jeżeli myślisz, że osoby nieuprawiające sportu nie doświadczają tego typu kontuzji... musimy Cię rozczarować. Codzienne sytuacje, niefortunne popchnięcie i śliska nawierzchnia również mogą doprowadzić do tego typu urazu. Jeżeli zastanawiasz się:jakie są objawy uszkodzonego więzadła pobocznego piszczelowego?jak wygląda rehabilitacja uszkodzonego MCL?czy po uszkodzeniu MCL zalecane są kule lub orteza?czy uszkodzenie MCL leczy się operacyjnie?c...2024-02-2136 min
Cut and RunS4 EP1 MCL Injuries. What is it and how is it injured?A discussion on MCL injuries. Learn everything you need to know about the MCL @cutandrunpodcast Season 4 Episode 1
What is the MCL? What is the function of the MCL?How is the MCL injured?What does it feel like to injure your ACL?Does it have the ability to heal?
Thanks for listening If you have any questions then send us an email at cutandrunpodcast@gmail.com to let us know if you have any topics you would like us to cover. See you next time.2024-02-0506 min
Where East Meets West with Dr. David CherianMCL Tears and Sports InjuriesMCL Tears, Sports Injuries and Xu Duan
The medial collateral ligament (MCL) runs on the inside of the knee, responsible for connecting the tibial and femur. It provides lateral stability when the knee joint is in motion, so when MCL injuries occur, it can compromise the knee’s ability to function.
MCL injuries are common in contact sports, where any impact that drives the knee inward can result in a strain or tear. Depending on the injury’s severity, an MCL tear can sideline an athlete or anyone else for months befor...2024-01-0807 min
Where East Meets West with Dr. David CherianMCL Tears and Sports InjuriesMCL Tears, Sports Injuries and Xu Duan
The medial collateral ligament (MCL) runs on the inside of the knee, responsible for connecting the tibial and femur. It provides lateral stability when the knee joint is in motion, so when MCL injuries occur, it can compromise the knee’s ability to function.
MCL injuries are common in contact sports, where any impact that drives the knee inward can result in a strain or tear. Depending on the injury’s severity, an MCL tear can sideline an athlete or anyone else for months befor...2024-01-0807 min
The Sports Docs Podcast62. Dr. Brett Owens: MCL Injuries - Part IIWe return today with Dr. Brett Owens to shift our discussion of MCL tears on to the treatment of isolated and combined MCL injuries, then wrap up with a discussion on safe return to play.Our conversation picks back up with a level 1 prospective multicenter RCT from the March 2022 issue of AJSM titled “Comparative Outcomes Occur After Superficial Medial Collateral Ligament Augmented Repair vs. Reconstruction.” Fifty-four patients with grade III MCL injuries were randomized to either MCL augmented repair or MCL reconstruction using a free semitendinosus autograft. At 1-year post-op, there was no difference in objective outcomes (incl...2023-12-1142 minThe Sports Docs Podcast61. Dr. Brett Owens: MCL Injuries - Part IOn today’s episode we’re focusing on medial collateral ligament injuries with Dr. Brett Owens. We’ll start off our discussion today with an article authored by our guest, Dr. Brett Owens, titled “The Epidemiology of Medial Collateral Ligament Sprains in Young Athletes” from the 2014 issue of AJSM.The authors performed a longitudinal cohort study of US military cadets and found that MCL injuries are relatively common in the athletic population. Male athletes are at significantly greater risk than females –of the 128 injuries in this study, 89% occurred in males. Intercollegiate athletes are also at greater risk than athlete...2023-12-0428 min
PeerView Internal Medicine CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
PeerView Internal Medicine CME/CNE/CPE Video PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
PeerView Clinical Pharmacology CME/CNE/CPE VideoNirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R DiseaseCovalent BTK inhibitors (cBTKi) have transformed the management of mantle cell...2023-11-251h 03
CCO Oncology PodcastA Year in Review and a Look to the Future: BTKi in CLL and MCLIn this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL ZUMA-2: Brexucabtagene Autoleucel in R/R MCL BRUIN: Pirtobrutinib for Previously Treated MCL ...2023-11-2027 min
CCO Oncology PodcastNew Evidence With BTK Inhibitor Therapy in MCL From ICML 2023In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL Presenters: Catherine C. Coombs, MD, MSAssociate Clinical ProfessorDivision of Hematology/Oncology, Department of MedicineUCI HealthOrange, CaliforniaToby Eyre, M...2023-08-1714 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14PeerView Oncology & Hematology CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14PeerView Clinical Pharmacology CME/CNE/CPE VideoProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14PeerView Internal Medicine CME/CNE/CPE Video PodcastProf. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative StrategiesGo online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this...2023-07-291h 14
OncotargetDecoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein StabilityA new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.”
The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), encouraged the development of inhibitors that target other antiapoptotic proteins, particularly Myeloid Leukemia 1 (MCL-1). MCL-1 is among the top genes amplified in several cancers and is implicated in cancer progression, drug resistance and poor prognosis. It protects cancer cells from apoptosis and decreases their sensitivity to targeted agents or chemotherapeutics.
In this new editorial, researchers Shad...2023-06-2802 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCLGo online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive...2023-03-0248 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCLGo online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive...2023-03-0248 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastJohn C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCLGo online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive...2023-03-0248 minPeerView Internal Medicine CME/CNE/CPE Video PodcastJohn C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCLGo online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive...2023-03-0248 minPeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL ManagementGo online to PeerView.com/YVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Across B-cell non-Hodgkin lymphoma settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell...2023-01-141h 19
Radio MCL Giovani RC ShowEpisodio 10 - Radio MCL Giovani RC ShowPuntata dedicata al Natale!2022-12-0640 minRadio MCL Giovani RC ShowRadio MCL Giovani RC Diretta Studio 01/12/2022Puntata dedicata all'amore.Con Francesca e Chiara!2022-12-0144 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 30/11/2022Seconda puntata dedicata alle canzoni italiane d'amore.Con Francesca e Chiara!2022-11-3047 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Live Studio 28/11/2022Puntata dedicata all'amore con canzoni italiane.Insieme a Francesca e Chiara2022-11-2844 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 25/11/2022Puntata dedicata alle donne!2022-11-2543 min
Radio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 22/11/2022Anche oggi puntata ricca di canzoni richieste dai nostri ascoltatori!!!2022-11-2245 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 17/11/2022Oggi una diretta sull'amicizia!!In studio Chiara e Francesca, con la regia del nostro Lele2022-11-1744 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 15/11/2022Anche oggi una diretta ricca di musica, oggi in studio con: Francesca e Chiara, in cabina di regia, Lele!!2022-11-1541 minRadio MCL Giovani RC ShowRadio MCL Giovani RC - Diretta Studio 09/11/2022Eccoci alla seconda puntata della nostra emittente radiofonica!!!!2022-11-0936 minRadio MCL Giovani RC ShowRADIO MCL GIOVANI - PUNTATA DI INAUGURAZIONEDa oggi è nata una nuova radio web!!!! RADIO MCL GIOVANI RC!!!2022-11-0715 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 minPeerView Clinical Pharmacology CME/CNE/CPE VideoDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 minPeerView Internal Medicine CME/CNE/CPE Video PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastDr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory DiseaseGo online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MC...2022-10-0559 min
CCO Oncology PodcastNew Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + ob...2022-08-3028 min
Lymphoma HubWhat is on the horizon for the frontline treatment of MCL?During the ASCO2022 congress, the Lymphoma Hub was pleased to speak with Anita Kumar, Memorial Sloane Kettering Cancer Center, New York, US. We asked, What is on the horizon for the frontline treatment of mantle cell lymphoma (MCL)? Kumar begins by discussing the historic treatment options for patients with MCL before highlighting that, in the future, clinicians hope to utilize information on clinical and biological baseline features that patients present with, and incorporate novel targeted therapies and MRD assessments to further individualize treatment for MCL. Kumar describes how increased pathobiological understanding has led to developments in t...2022-07-2507 min
CCO Oncology PodcastNew Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphomaPhase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL o...2022-07-0632 min
Chimeric antigen receptor (CAR) t-cell therapy - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 min
Mantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minEpisodes - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minTreatment - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minEnglish - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minLymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 min
English – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minTreatment – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minChimeric antigen receptor (CAR) t-cell therapy - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minThe Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell TherapyJoin us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has … Mantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy Read More »2022-05-2334 minLymphoma – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part Two: CAR T-Cell Therapy
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part Two of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the development and utilization of CAR T-cell therapy for MCL. Approved in July of 2020 for relapsed or refractory MCL, CAR T-cell therapy has shown incredible promise and is already giving hope to patients and doctors as a potential cure.
Be sure to tune into Part 1, where Dr. Lampson discussed the current treatments and latest advances for MCL.
DOWNLOAD TRANSCRIPT
CLICK HERE...2022-05-2334 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minTreatment – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment Advances
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minEpisodes - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minCoronavirus (COVID-19) - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minLymphoma – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment Advances
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minTreatment - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minEnglish - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minEnglish – The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment Advances
Benjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 minLymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) Part One: Treatment AdvancesBenjamin Lampson, MD, PhD
Join us as we speak to Dr. Benjamin Lampson of Dana-Farber Cancer Institute in Boston, MA. In Part One of this two-part series on mantle cell lymphoma (MCL), Dr. Lampson discusses the latest treatment advances for MCL. With more treatments available than just a few years ago, Dr. Lampson shares how his conversations with his patients have changed, providing more hope after a diagnosis of MCL.
Be sure to tune into Part 2 launching on May 23, 2022, where Dr. Lampson will focus on the exciting possibilities of CAR T-cell therapy for MCL.
DOWNLOAD TRANSCRIPT
...2022-05-1638 min
Le Voci del volontariatoIntervista a Margherita Peroni, Presidente Movimento Cristiano Lavoratori Unione territoriale di Brescia – Mantova (MCL)Margherita Peroni, Presidente Movimento Cristiano Lavoratori Unione territoriale di Brescia – Mantova (MCL) una realtà che quest’anno, a livello nazionale e provinciale, compie 50 anni.MCL è un ente di promozione sociale che si ispira alla dottrina sociale della Chiesa e si occupa di diversi servizi per i lavoratori e le famiglie.MCL offre servizi di CAF, patronato per i lavoratori ed è impegnato per la formazione, prima di tutto culturale, ma anche specifica per aiutare i lavoratori a comprendere i cambiamenti, il senso di quello che sta avvenendo con un’attenzione particolare al mondo dei giovani. I volontari sono da s...2022-03-2207 min
This Must Be The Place: The Building Science PodcastBrad McLaughlin - MCL Construction Ltd.In this episode of This Must be The Place Shawna exchanges net-zero knowledge and industry best practices with Brad McLaughlin. He is the General Manager of the multi-award winning company MCL Construction Ltd. based in New Brunswick, Canada. MCL has been serving the greater Saint John area for over 40 years specializing in building custom homes and renovations.
In this episode:
• MCL was featured on CBC for building the first net zero home in the province. Yet, it sat on the market for longer than anticipated. Tune in to find out if it eventually sold and wh...2022-01-2750 min
Cult Of OddEpisode 57: An MCL Xmas EveThis is 1 of 2 last episodes of The Odd Podd, catch #interviewroulette with Mark Christopher Lawrence! We've got terrifying Christmas traditions from around the world and Interesting facts about Christmas you might not know. MCL is best known for his series regular role as Big Mike on the NBC TV series CHUCK. He recently completed production on the hit ADULT SWIM TV show BLACK JESUS and is recurring on The PureFlix Show Malibu Dan The Family Man. He can be seen on the Disney Channel’s original TV movie Life Is Ruff and guest appearances on Lab Rats, Good Luck Char...2021-12-261h 07
Cult Of OddEpisode 57: An MCL Xmas EveThis is 1 of 2 last episodes of The Odd Podd, catch #interviewroulette with Mark Christopher Lawrence! We've got terrifying Christmas traditions from around the world and Interesting facts about Christmas you might not know. MCL is best known for his series regular role as Big Mike on the NBC TV series CHUCK. He recently completed production on the hit ADULT SWIM TV show BLACK JESUS and is recurring on The PureFlix Show Malibu Dan The Family Man. He can be seen on the Disney Channel’s original TV movie Life Is Ruff and guest appearances on Lab Rats, Good Luck Char...2021-12-261h 07Lymphoma HubWhat does real-world data tell us about frontline treatment strategies for MCL?During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Michael Wang, MD Anderson Cancer Center, Houston, US, and Peter Martin, Weill Cornell Medicine, New York, US. We asked, What does real-world data tell us about frontline treatment strategies for mantle cell lymphoma (MCL)? To answer this question, Martin firstly evaluates data from a retrospective study, which included adult patients with MCL in the nationwide Flatiron Health EHR-derived deidentified database. He describes the results in 3,455 previously untreated patients, including treatment patterns in real-world clinical practice and how they compare with clinical studies, patient outcomes, and the...2021-06-2913 min
hodpodcastWhat You Should (and Shouldn't) Do After ACL and MCL Tears and SurgeryRegardless of whether you harmed your knee on the inclines, in the exercise center, on the field or from a slip and fall, returning to 100% after knee medical procedure can feel like a daunting task.As a rule, that is on the grounds that it is.Restoring from ACL or MCL medical procedure is a long cycle – and that interaction starts the second you conscious from sedation.Upper leg tendon versus MCL Tears and SurgeryUpper leg tendon (foremost cruciate tendon) tears and MCL (average security tendon) tears are the two mo...2021-05-2802 min
Blood & CancerHow I treat CLL and MCL: From ‘watch and wait’ to BCL2 and BTK inhibitors, CAR T-cell therapy, and transplantTreatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) have advanced in recent years, with more new developments on the horizon. James Gerson, MD, of the University of Pennsylvania, Philadelphia, reviewed some of these advances and future directions while describing how he would treat three patients. Host David H. Henry, MD, posed the following cases for consideration. Case 1 In a 75-year-old male with no comorbid illness, routine blood work revealed a WBC count of 15,000/mcL. The manual differential showed mature lymphocytes and smudge cells. The patient has no constitutional symptoms, but...2021-03-1122 minThe New Grad Physio PodcastMCL Knee Injury Rehab - From The Bed To The FieldMCL (medial collateral ligament)injuries are very common but there are a lot of misconceptions about how to rehab these injuries.
When do you start?
Can you do exercises in the brace?
What exercises do you do?
How do you know when your athlete is ready to start running?
How do you know when they are ready to rejoin full training or do contact work?
If you want to know the answers to any or all of these questions then you are in the right place!
2021-02-2525 min
Rodinné podnikanieŠtruktúra a výhody rodinného holdinguKaždé rodinné podnikanie prechádza svojimi vývojovými štádiami. Na začiatku je to predovšetkým o vyhľadávaní a využívaní príležitostí, neskôr podnikanie rastie a pomaly dozrieva a prichádza čas poupratovať, konsolidovať a stabilizovať. Vhodným nástrojom konsolidácie rodinného podnikania a majetku je rodinný holding. V ďalšej časti podcastu Rodinné podnikanie sa Michal Šubín z Family office spoločnosti RSM CZ&SK a Matej Firický, partner advokátskej kancelárie MCL spoločne podelia s praktickými skúsenosťami týkajúcimi sa motivácie a cieľov spojených s konsolidáciou...2020-12-2949 minLymphoma HubCan we eliminate auto-SCT for patients with MCL?During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Marco Ladetto, SS Antonio e Biagio e Cesare Arrigo, Alessandria, IT, who discussed the role of autologous stem cell transplant (auto-SCT) for mantle cell lymphoma (MCL) in 2020.Marco Ladetto starts by introducing what role auto-SCT plays in MCL and indicates that it must be considered in the context of full treatment protocols. He goes on to say, however, that medicine must continue to advance, and one way in which this can be done is through examination o...2020-11-1105 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minLymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minEnglish – The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should Know
Benjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minEnglish - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minLymphoma – The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should Know
Benjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minMantle cell lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minEpisodes - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 minNon-Hodgkin lymphoma - The Bloodline with LLSMantle Cell Lymphoma (MCL) with Dr. Benjamin Lampson: What Patients Should KnowBenjamin Lampson, MD
Join Alicia, Lizette and Edith as they speak with Dr. Benjamin Lampson. Dr. Lampson is an instructor in medicine at Dana-Farber Cancer Institute. On this episode, Dr. Lampson explains how mantle cell lymphoma (MCL) is diagnosed and treated. Dr. Lampson gives his advice for MCL patients during the coronavirus (COVID-19) pandemic. He also shares the long-term effects of treatment, the future of treatment for MCL, clinical trials and when they are considered for treatment for lymphoma patients, and the importance of open communication between a patient and their healthcare team.
Download Transcript
CLICK HERE to pa...2020-07-1343 min
MCL Recording Co.SMDS - Defines the TimeDefines The Time is a new psyche single by SMDS released Feb 3, 2017 on MCL Recording Co.
SMDS is the collaboration project between MCL Recording artists Solar Maximum, a dual bass psyche-drone duo and experimental sound fiend DS Peligro.
Solar Max - https://soundcloud.com/solar-maximum
DS Peligro - https://soundcloud.com/davidspeligro
pallasCatfight - https://soundcloud.com/pallascatfight
Buy Defines theTime at: https://mclrecordingco.bandcamp.com/track/smds-defines-the-time-single
video at Youtube: https://youtu.be/qY128GY1xq8
Credits:
Sammy Chong Salazar - bass, keys, recording
Heather Salazar - astro-bass, noises
DS Peligro - noises, sounds, mix/mastered
Diamond Joe L...2017-01-3007 min
AwesomonsterAWSM Comedy Radio EP 180 with Abby Vatterott and Logan Hulick of MCLOMG MCL meets AWSM at CBA. Yes, that is all accurate and real. So, listen in and meet Abby Vatterott and Logan Hulick and check out the awesome, weekly variety show at MCL on Tuesdays at 10:00p.m. featuring improv, sketch, stand-up, music, storytelling and more. We love more.
The show is BYOB, $7 and located at MCL, 3110 N Sheffield in Chicago!
Connecting awesome people, laughing like monsters.
AWSM
Awesomonster2016-01-1418 min
Medizin - Open Access LMU - Teil 18/22Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1.Melanoma is an often fatal form of skin cancer which is remarkably resistant against radio- and chemotherapy. Even new strategies that target RAS/RAF signaling and display unprecedented efficacy are characterized by resistance mechanisms. The targeting of survival pathways would be an attractive alternative strategy, if tumor-specific cell death can be achieved. Bcl-2 proteins play a central role in regulating survival of tumor cells. In this study, we systematically investigated the relevance of antiapoptotic Bcl-2 proteins, i.e., Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1, in melanoma cell lines and non-malignant cells using RNAi. We found that melanoma cells required the...2012-01-0100 minMedizin - Open Access LMU - Teil 17/22Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1Background: Human renal cell carcinoma (RCC) is very resistant to chemotherapy. ABT-737 is a novel inhibitor of antiapoptotic proteins of the Bcl-2 family that has shown promise in various preclinical tumour models. Results: We here report a strong over-additive pro-apoptotic effect of ABT-737 and etoposide, vinblastine or paclitaxel but not 5-fluorouracil in cell lines from human RCC. ABT-737 showed very little activity as a single agent but killed RCC cells potently when anti-apoptotic Mcl-1 or, unexpectedly, A1 was targeted by RNAi. This potent augmentation required endogenous Noxa protein since RNAi directed against Noxa but not against Bim or Puma reduced...2010-01-0100 min